88 completed, 18 terminated, 13 unknown, 4 active not recruiting. 68 Phase 2, 34 Phase 1, 27 Phase 3, 5 Not applicable, 5 Phase 4.
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| Interferon Alpha Therapy for Cervical CINI and HPV Infection gel Interferon arm, gel Interferon and interferon suppository arm - Cervical Dysplasia, HPV Infection | Phase 1 | Completed | Mongolian National University of Medical Sciences | 60 | 2023-11-07 | 2025-04-03 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 12 | 2019-11-29 | 2026-06-09 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Biopsy, Chemokine Modulation Therapy, Celecoxib - Triple -Negative Breast Cancer, Estrogen Receptor Negative | Early Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2019-01-09 | 2023-07-18 |
| To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs. Nucleotide Analog, Interferon Alfa-2A - Hepatitis B | Not applicable | Unknown | Sun Yat-sen University | 400 | 2018-12-01 | 2023-05-08 |
| Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients Interferon Alfa 2a - Chronic Hepatitis b, Efficacy, Self | Not applicable | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 100 | 2018-11-15 | 2018-11-23 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 12 | 2018-08-01 | 2021-04-01 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2018-04-19 | 2022-03-02 |
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
| Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis BMS-986202, Placebo, Interferon alpha-2a recombinant - Psoriasis | Phase 1 | Completed | Bristol-Myers Squibb | 357 | 2016-05-18 | 2017-08-03 |
| Interferon-α After DLI for the Prevention of Relapse Interferon Alfa-2b - Leukemia | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 42 | 2015-12-01 | 2016-09-29 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
| Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis BMS-986165, Interferon alpha-2a recombinant, Famotidine - Healthy Subjects | Phase 1 | Completed | Bristol-Myers Squibb | 140 | 2015-10-01 | 2016-12-28 |
| Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection TG-2349, Ribavirin, Interferon Alfa-2a - Hepatitis C, Chronic | Phase 2 | Completed | TaiGen Biotechnology Co., Ltd. | 25 | 2015-05-01 | 2023-07-14 |
| Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b Pembrolizumab and high dose interferon alfa-2b (HDI) - Melanoma | Phase 1 | Completed | Yana Najjar | 31 | 2015-03-06 | 2021-02-24 |
Showing 20 of 128. Sign in to see all of them.
Melanoma (22) · Carcinoma, Renal Cell (19) · HIV Infections (15) · Hepatitis C (10) · Acquired Immunodeficiency Syndrome (9) · Hepatitis C, Chronic (8) · Hepatitis B, Chronic (5) · Leukemia (5) · Sarcoma, Kaposi (5) · AIDS-Related Complex (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma (4) · Neoplasm Metastasis (4) · Hematologic Neoplasms (3) · Kidney Neoplasms (3)
M.D. Anderson Cancer Center (15) · National Cancer Institute (NCI) (12) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Roswell Park Cancer Institute (8) · Hoffmann-La Roche (7) · Merck Sharp & Dohme LLC (5) · Beijing Bio-Fortune Ltd. (2) · Bristol-Myers Squibb (2) · Case Comprehensive Cancer Center (2) · Centre Leon Berard (2) · Foundation for Liver Research (2) · Leiden University Medical Center (2) · National Taiwan University Hospital (2) · Peking University People's Hospital (2) · University Hospital Tuebingen (2)
United States (69) · China (10) · Germany (10) · France (9) · Canada (8) · Netherlands (8) · Italy (6) · Spain (6) · Switzerland (6) · United Kingdom (6) · Australia (5) · Russia (5) · Poland (4) · Puerto Rico (4) · Taiwan (4)
Ahmad Tarhini (2) · Fischl MA (2) · Igor Puzanov (2) · William Carson (2) · Agop Y. Bedikian, MD (1) · Alberto S. Pappo, MD (1) · Alexandre Frederico, Doctor (1) · Alvarado Beatriz, M.D. (1) · Amar Safdar, MD (1) · Amer H Zureikat, MD (1) · Ana M. Aparicio, MD (1) · Anas Younes, MD (1) · Andrew Muir, M.D. (1)
PMID 37146227, PMID 15079763, PMID 15256423, PMID 15282352, PMID 15563253, PMID 15685543, PMID 15867490, PMID 16115185, PMID 16439867, PMID 17215529, PMID 17932908, PMID 18317583, PMID 19430405, PMID 19622576, PMID 20104222, PMID 20622678, PMID 21664867, PMID 23402397, PMID 23620574, PMID 23803225, PMID 24316557, PMID 25304727, PMID 25577718, PMID 25649350, PMID 25686644, PMID 25851632, PMID 25900027, PMID 27101285, PMID 27238653, PMID 27287206, PMID 28291640, PMID 28384065, PMID 28410911, PMID 28457953, PMID 28620382, PMID 28835440, PMID 29152412, PMID 29392960, PMID 29563634, PMID 29774030, PMID 29853320, PMID 30711970, PMID 30885996, PMID 31371315, PMID 32103499, PMID 32228710, PMID 32299817, PMID 32632956, PMID 33214615, PMID 34327591
P30CA016672 (6), P01CA234212 (3), 2004 (2), U10CA021115 (2), U10CA180820 (2), U10CA180888 (2), U24CA196172 (2), 2008 (1), 2014 (1), N01CM17101 (1), N01CM62202 (1), P01CA128115 (1), P01CA132714 (1), P30CA016056 (1), P30CA016058 (1)